Galectin Therapeutics (GALT)
(Real Time Quote from BATS)
$2.56 USD
+0.04 (1.59%)
Updated Jul 17, 2024 02:30 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GALT 2.56 +0.04(1.59%)
Will GALT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GALT
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
GALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Other News for GALT
Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics GAAP EPS of -$0.19